U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C29H36N2O9
Molecular Weight 556.6041
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CINEPAXADIL

SMILES

COC1=CC(\C=C\C(=O)N2CCN(CC(O)COC3=C4OCCOC4=C(C=C3)C(C)=O)CC2)=CC(OC)=C1OC

InChI

InChIKey=SYFDPNLESAYNCB-VMPITWQZSA-N
InChI=1S/C29H36N2O9/c1-19(32)22-6-7-23(29-27(22)38-13-14-39-29)40-18-21(33)17-30-9-11-31(12-10-30)26(34)8-5-20-15-24(35-2)28(37-4)25(16-20)36-3/h5-8,15-16,21,33H,9-14,17-18H2,1-4H3/b8-5+

HIDE SMILES / InChI
Molecular Formula C29H36N2O9
Molecular Weight 556.6041
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 1
Optical Activity ( + / - )

Description

Cinepaxadil is cinnamoyl-piperazine derivative developed by Delalande SA for treatment cardiovascular system disorders. Cinepaxadil decrease dogs cardiac activity after i.v. administration.

Originator

Delalande S. A.
6

Approval Year

Unknown
149,124

PubMed

Patents

DE2816785
1

Sample Use Guides

In Vivo Use Guide
2.5 mg​/kg i.v. in dogs
Route of Administration: Intravenous
Substance Class Chemical
Record UNII
E052L8N506
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966